OPKO HEALTH INC (OPK)
Health Care · Specialty pharmaceuticals and clinical diagnostics · NASDAQ
OPKO Health combines specialty pharmaceuticals (long-acting growth hormone and hyperparathyroidism treatments) with clinical diagnostics and laboratory testing, but faces steep revenue headwinds and persistent losses.
What OPKO HEALTH INC does
OPKO Health is a diversified healthcare company with three main operating segments: diagnostics and laboratory services (including clinical testing through BioReference), specialty pharmaceuticals (including long-acting Somatrogon/NGENLA for growth hormone deficiency and Rayaldee for secondary hyperparathyroidism), and drug development through its ModeX Therapeutics subsidiary. The company is moving through a period of significant revenue decline and operating losses while seeking to stabilize its pharmaceutical commercialization efforts and laboratory operations.
Themes: ["Specialty pharmaceuticals / endocrinology","Clinical diagnostics and laboratory testing","Growth hormone deficiency treatment","Secondary hyperparathyroidism","Prostate cancer diagnostics","GLP-1 therapeutics (partnered development)","Drug development / R&D pipeline"]
Fundamentals
- Price$1.39 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+0.7% as of 2026-07-09 close
- Net margin-36.5% as of 2026-07-10
- Gross margin+38.0% as of 2026-07-10
- ROE-16.7% as of 2026-07-10
- Debt / equity0.29 as of 2026-07-10
- Revenue growth (YoY)-29.0% as of 2026-07-10
- Revenue CAGR (3y)-15.5% SEC XBRL
- Beta1.47 as of 2026-07-10
Key risks (from latest filing)
["History of operating losses and inability to achieve sustained positive cash flow; may require additional financing or reduced R&D spending","Significant revenue decline (-29% YoY) with reimbursement pressures from payors; reliance on distribution partners and laboratory client retention","Regulatory and compliance risks including ongoing Corporate Integrity Agreement with HHS OIG and potential product liability or patent infringement disputes"]
Competitors & peers
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Pfizer (PFE)
- Ascensus Pharma (somatrogon/growth hormone)
- Amgen (AMGN)
- Quest Diagnostics (DGX)
- LabCorp (LH)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.